The past couple of years have been a whirlwind for cannabidiol (CBD), one of the major cannabinoids extracted from the hemp (marijuana) plant. Cannabis is perhaps most known for the psychoactive high its users experience after using it. THC (delta-9 tetrahydrocannabinol) is the compound responsible for this high, but CBD has often been lumped together with its psychoactive cousin.
Demand for CBD products has boomed lately, primarily driven by consumers looking to alleviate a variety of medical conditions. Cannabidiol has proved efficient against diseases ranging from anxiety and chronic pain to epilepsy. In 2018, the World Anti-Doping Agency removed CBD from its list of banned substances, thereby opening the door for…
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor